Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.123

Abstract

Background. The cost-of-illness (COI) analysis allows to estimate and plan costs for calculations between the subjects of the health care system and medical insurance organizations. The primary morbidity of the population with diseases of the circulatory system increased from 4,784 thousand people in 2018 to 5,136 thousand in 2019. A growth in the number of cases resulted in an increase in the demand for drugs for the treatment of cardiovascular diseases.

Objective: to perform a pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents by COI-analysis.

Material and methods. The source of information for COI-analysis was the real clinical practice – medical records of sick children and adolescents. A pharmacoeconomic study using COI-analysis was carried out at the inpatient and outpatient stages of care and included the calculation of direct medical costs (the costs of laboratory, instrumental medical services, non-drug and drug antihypertensive therapy). The study included 102 children diagnosed with arterial hypertension. The average stay of patients in the hospital was 10 (10.4±0.35) bed-days and treatment on an outpatient basis varied from 3 months to 1 year.

Results. The leading place in the structure of costs for antihypertensive therapy is occupied by the beta-blockers pharmacological group (35%). The total cost of arterial hypertension in children and adolescents in inpatient and outpatient settings was 4,459.00 and 29,638.90 rubles, respectively.

Conclusion. The COI-analysis of arterial hypertension confirms the need for timely diagnosis and treatment and preventive measures for high blood pressure in children and adolescents to reduce the development of risk factors for such serious cardiovascular complications as stroke and myocardial infarction in adulthood, the treatment of which requires large cash costs.

About the Authors

O. S. Mikhaylova
Smolensk State Medical University
Russian Federation

Olga S. Mikhaylova – Faculty Member, Chair of Pharmacy Management and Economics. RSCI SPIN-code: 6418-8014

28 Krupskaya Str., Smolensk 214019



A. V. Krikova
Smolensk State Medical University
Russian Federation

Anna V. Krikova – Dr. Pharm. Sc., Professor, Chief of Chair of Pharmacy Management and Economics. Scopus Author ID: 25653569200; RSCI SPIN-code: 6763-2194

28 Krupskaya Str., Smolensk 214019



References

1. Federal State Statistics Service. Russian Statistical Yearbook. Available at: https://rosstat.gov.ru/folder/210/document/12994 (in Russ.) (accessed 12.06.2021).

2. DSM Group analytical report on the pharmaceutical market of Russia. Results of 2020 Available at: https://dsm.ru/upload/iblock/cf9/cf90a8be2be6374d636c6cc65bc96860.pdf (in Russ.) (accessed 12.06.2021).

3. Decree of the Government of the Russian Federation of 30.07.1994 No. 890 “On state support for the development of the medical industry and improving the provision of medicines and medical products to the population and health care institutions”. Available at: https://base.garant.ru/101268/ (in Russ.) (accessed 12.06.2021).

4. Decree of the Government of the Russian Federation of 01.12.2004 No. 715 “On approval of the list of socially significant diseases and the list of diseases posing a danger to others”. Available at: https://base.garant.ru/12137881/ (in Russ.) (accessed 12.06.2021).

5. Yagudina R.I., Zinchuk I.Yu., Litvinenko М.M. Cost of illness analysis: types, methodology, Russian specifics. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012; 5 (1): 4–9 (in Russ.).

6. Yagudina R.I., Kulikov A.Yu, Serpik V.G., Logvinyuk P.A. Pharmacoeconomics and drug provision: cardiovascular diseases. Rostov-on-Don: Feniks; 2019: 174 pp. (in Russ.).

7. Krikova A.V., Mikhailova O.S., Kozlova L.V. Analysis of nomenclature of hypotensive medicines used in children and adolescents. Vestnik of the Smolensk State Medical Academy. 2020; 19 (4): 164–73 (in Russ.). https://doi.org/10.37903/vsgma.2020.26.

8. Federal Law of 08.12.2017 No. 326-FZ “On compulsory medical insurance in the Russian Federation”. Available at: https://base.garant.ru/12180688/ (in Russ.) (accessed 12.06.2021).

9. Decree of the Government of the Russian Federation of 08.12.2017 No. 1492 “On the program of state guarantees of free medical care to citizens for 2018 and for the planning period of 2019 and 2020”. Available at: https://www.garant.ru/products/ipo/prime/doc/71729300/ (in Russ.) (accessed 12.06.2021).

10. Aleksandrov A.A., Kisliak O.A., Leontyeva I.V. Clinical guidelines on arterial hypertension diagnosis, treatment and prevention in children and adolescents. Systemic Hypertension. 2020; 17 (2): 7–35 (in Russ.). https://doi.org/10.26442/2075082X.2020.2.200126.

11. Leontyeva I.V. Treatment of hypertension in children and adolescents. Rossiyskiy Vestnik Perinatologii i Pediatrii / Russian Bulletin of Perinatology and Pediatrics. 2019; 64 (1): 15–24 (in Russ.). https://doi.org/10.21508/1027-4065-2019-64-1-15-24.

12. Order of the Government of the Russian Federation of 10.12.2018 No. 2738-r “On approval of the list of vital and essential medicines for medical use for 2019, the list of medicines for medical use, the list of medicines intended to provide persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, persons after transplantation of organs and (or) tissues, as well as the minimum range of medicines necessary for the provision of medical care”. Available at: https://www.garant.ru/products/ipo/prime/doc/72023048/ (in Russ.) (accessed 12.06.2021).

13. Decree of the Administration of the Smolensk Region of 22.10.2010 No. 809 (ed. of 21.02.2018 No. 98) “On the establishment of the maximum sizes of wholesale allowances and the maximum sizes of retail allowances to the actual selling prices, set by manufacturers of medicines, for medicines included in the list of vital and essential medicines”. Available at: https://dpt.admin-smolensk.ru/files/279/post_adm_so_22_12_2010_809.pdf (in Russ.) (accessed 12.06.2021).

14. Yagudina R.I. The pharmacoeconomic analysis of treatment of the arterial hypertension by bisoprolol at hospital and out-patient stages. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2009; 2 (1): 25–31 (in Russ.).

15. Tarlovskaya E.I., Mal’chikova S.V. Comparative analysis of total disease costs in patients with arterial hypertension: the results of the open, multi-centre observational programme “PRORYV”. Russian Journal of Cardiology. 2012; 6: 78–83 (in Russ.).


Review

For citations:


Mikhaylova O.S., Krikova A.V. Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(2):199-208. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.123

Views: 207


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)